Safer anticoagulant therapy after heart valve replacement: Recommendations for less intense regimens

Postgraduate Medicine

Volumn 101, Issue 3, 1997, Pages

  Turpie, A G G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; WARFARIN;

ANTICOAGULANT THERAPY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART VALVE REPLACEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; THROMBOEMBOLISM;

EID: 1842404744     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.03.182     Document Type: Review

References (20)

1. Larsen GL, Alexander JA, Stanford W. Thromboembolic phenomena in patients with prosthetic aortic valves who did not receive anticoagulants. Ann Thorac Surg 1977;23(4):323-6
2. Limet R, Lepage G, Grondin CM. Thromboembolic complications with the cloth-covered Starr-Edwards aortic prosthesis in patients not receiving anticoagulants. Ann Thorac Surg 1977;23(6):529-33
3. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102(4 Suppl):445-55S
4. Levine MN, Hirsh J, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102(4 Suppl):352-63S
5. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307(27):1676-81
6. Turpie AG, Gunstensen J, Hirsh J, et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1(8597):1242-5
7. Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322(7):428-32
8. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101(3):427-31
9. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992;102(4 Suppl): 312-26S
10. Cevese PG. Long term results of 212 xenograft valve replacements. J Cardiovasc Surg (Torino) 1975;16(6):639-42
11. Ionescu MI, Pakrashi BC, Mary DA, et al. Long-term evaluation of tissue valves. J Thorac Cardiovasc Surg 1974;68:361-79
12. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108(4 Suppl): 371-79S
13. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333(1): 11-7
14. Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971;284(25):1391-4
15. Fuster V, Badimon L, Badimon JJ, et al. Prevention of thromboembolism induced by prosthetic heart valves. Semin Thromb Hemost 1988;14(1):50-8
16. Dale J, Myhre E, Storstein O, et al. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977;94(1):101-11
17. Hirsh J, Salzman EW, Harker L, et al. Aspirin and other platelet active drugs: relationship among dose, effectiveness, and side effects. Chest 1989; 95(2 Suppl):12-8S
18. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-9
19. Rajah SM, Sreeharan A, Joseph A, et al. A prospective trial of dipyridamole and warfarin in heart valve patients. (Abstr) Acta Ther 1980;6(Suppl 93):54
20. Groupe de Recherche P.A.C.T.E. Prevention des accidents thromboemboliques systemiques chez les porteurs de protheses valvulaires artificielles: essai cooperatif controle du dipyridamole. Coeur 1978;9(4):915-69